tetano
Editor, Senior Moderator
Methods Mol Biol
. 2022;2410:193-208.
doi: 10.1007/978-1-0716-1884-4_9.
Design of Replication-Competent VSV- and Ervebo-Vectored Vaccines Against SARS-CoV-2
Qixing Liu[SUP] 1 [/SUP], Zhe Ding[SUP] 1 [/SUP], Jiaming Lan[SUP] 1 [/SUP], Gary Wong[SUP] 2 3 [/SUP]
Affiliations
Abstract
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a global public health emergency. Several vaccine candidates have been developed in response to the COVID-19 pandemic. One approach is to construct live-recombinant viruses expressing the SARS-CoV-2 spike protein (S) as vaccine candidates. The vesicular stomatitis virus (VSV) vector is a mature vaccine platform which was successfully developed as a vaccine against Ebola virus (EBOV), leading to its licensure by the Food and Drug Administration (FDA) in December 2019. Based on this work, we developed two live, replication-competent VSV-vectored vaccines against SARS-CoV-2: (1) a VSV expressing the S protein of SARS-CoV-2 and (2) a bivalent VSV expressing the S protein of SARS-CoV-2 and the glycoprotein (GP) of EBOV. This protocol describes the methodologies for the design, cloning, rescue, and preparation of these recombinant VSV vaccines.
Keywords: Ervebo; Reverse genetics system; SARS-CoV-2; Spike protein; Vaccine; Vesicular stomatitis virus.
. 2022;2410:193-208.
doi: 10.1007/978-1-0716-1884-4_9.
Design of Replication-Competent VSV- and Ervebo-Vectored Vaccines Against SARS-CoV-2
Qixing Liu[SUP] 1 [/SUP], Zhe Ding[SUP] 1 [/SUP], Jiaming Lan[SUP] 1 [/SUP], Gary Wong[SUP] 2 3 [/SUP]
Affiliations
- PMID: 34914048
- DOI: 10.1007/978-1-0716-1884-4_9
Abstract
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a global public health emergency. Several vaccine candidates have been developed in response to the COVID-19 pandemic. One approach is to construct live-recombinant viruses expressing the SARS-CoV-2 spike protein (S) as vaccine candidates. The vesicular stomatitis virus (VSV) vector is a mature vaccine platform which was successfully developed as a vaccine against Ebola virus (EBOV), leading to its licensure by the Food and Drug Administration (FDA) in December 2019. Based on this work, we developed two live, replication-competent VSV-vectored vaccines against SARS-CoV-2: (1) a VSV expressing the S protein of SARS-CoV-2 and (2) a bivalent VSV expressing the S protein of SARS-CoV-2 and the glycoprotein (GP) of EBOV. This protocol describes the methodologies for the design, cloning, rescue, and preparation of these recombinant VSV vaccines.
Keywords: Ervebo; Reverse genetics system; SARS-CoV-2; Spike protein; Vaccine; Vesicular stomatitis virus.